<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408069</url>
  </required_header>
  <id_info>
    <org_study_id>ACHEMS0211</org_study_id>
    <nct_id>NCT01408069</nct_id>
  </id_info>
  <brief_title>Non-Inferiority Comparison of Migrane速 Versus Parcel 速 For Treatment of Tensional Cephaleia</brief_title>
  <official_title>Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane速 Versus Parcel 速 For Treatment Of Tensional Cephaleia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority clinical efficacy of two&#xD;
      different associations of drugs in the treatment of patients diagnosed with tensional-type&#xD;
      headache in accordance with International Headache Society guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Open-label, non-inferiority, prospective, parallel group, intent to treat trial.&#xD;
&#xD;
        -  Experiment duration: 56 days.&#xD;
&#xD;
        -  04 visits (days -7, 0, 28 and 56).&#xD;
&#xD;
        -  Efficacy will be evaluated for 10 episodes of tension-type headache.&#xD;
&#xD;
        -  Adverse events evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study canceled by decision strategically.&#xD;
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment in relieve headache symptoms.</measure>
    <time_frame>1 hour</time_frame>
    <description>The evaluation of efficacy will be determined based on comparison of the intensity of headache before and after 30, 60 and 90 minutes of initiation of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of study treatment</measure>
    <time_frame>56 days</time_frame>
    <description>Tolerability will be assessed by the investigator through the number of adverse events definitely related to study medication. This relationship will be defined by applying the Naranjo algorithm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Tensional-type Headache</condition>
  <arm_group>
    <arm_group_label>MIGRANE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PARCEL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIGRANE</intervention_name>
    <description>1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)</description>
    <arm_group_label>MIGRANE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PARCEL</intervention_name>
    <description>1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)</description>
    <arm_group_label>PARCEL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be able to understand the study procedures agree to participate and give&#xD;
             written consent.&#xD;
&#xD;
          2. Tensional-type headache patients according to the International Headache Society&#xD;
             criteria.&#xD;
&#xD;
          3. Corporal body indices &lt; 40.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or risk of pregnancy.&#xD;
&#xD;
          2. Lactation&#xD;
&#xD;
          3. Use of acetylsalicylic acid or corticosteroids or immunosuppressive therapy.&#xD;
&#xD;
          4. Use of immunosuppressive drugs.&#xD;
&#xD;
          5. Alterations of laboratory selective tests.&#xD;
&#xD;
          6. Drugs or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>headache</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

